Article Sidebar

PDF
Date Published: 08/01/2022
Abstract Views: 195
Views PDF: 152
DOI: https://doi.org/10.51298/vmj.v508i2.1654
Issue
Vol. 508 No. 2 (2021)
Section
Các bài báo
How to Cite
Chí Hiếu, K. ., & Thị Huyền, P. . (2022). EVALUATING RESULTS OF PACLITAXEL CARBOPLATIN IN THE TREATMENT OF RECURRENT ENDOMETRIAL CANCER, IN K HOSPITAL. Vietnam Medical Journal, 508(2). https://doi.org/10.51298/vmj.v508i2.1654

EVALUATING RESULTS OF PACLITAXEL CARBOPLATIN IN THE TREATMENT OF RECURRENT ENDOMETRIAL CANCER, IN K HOSPITAL

Khúc Chí Hiếu1,, Phùng Thị Huyền1
1 Tân Triều Brach of National Cancer Hospital

Main Article Content

Abstract

Objectives: Evaluation of Overall Response Rate and Progression Free Survival in patients with recurrent endometrial cancer treated with paclitaxel carboplatin. Materials and methods: A retrospective and prospective descriptive study was conducted on 54 recurrent endometrial cancer patients received Paclitaxel Carboplatin in K hospital. Results: The overall response rate was 75,9%; complete response was 31,5%; partial response account 44,4%. Stable disease was recorded as 11,1%, 13% of patients disease progresses. Median of progression free survival was 6 month.  Conclusions: Paclitaxel carboplatin regimen is effective in recurrent endometrial cancer patients.

Article Details

Keywords

Recurrent endometrial cancer patients

References

1. Nguyễn Bá Đức (2007), Chẩn đoán và điều trị ung thư, NXB Y học
2. Bùi Diệu, (2011), Một số bệnh ung thư phụ nữ, NXB Y học.
3. Đặng Tiến Giang và cộng sự (2020). Bước đầu đánh giá kết quả phác đồ lyposomal doxorubicin trên bệnh nhân ung thư nội mạc tử cung tái phát tại bệnh viện K. Tạp chí y học Việt Nam, 497, 45-48.
4. Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008;109(2):250-254. doi:10.1016/ j.ygyno.2008.01.028
5. Cohen CJ. Cytotoxic chemotherapy for patients with endometrial carcinoma. Clin Obstet Gynaecol. 1986;13(4):811-824 .
6. Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020; 38(33):3841-3850. doi:10.1200/JCO.20.01076.
7. Trope CG, Alektiar KM, Sabbatini P, Zaino RJ. Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins;2005:823-872.
8. Huijgens ANJ, Mertens HJMM. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013;5(3):179-186.